Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRDye800CW-nimotuzumab in Lung Cancer Surgery
NCT04459065Phase 2Recruiting
- Sponsor
- University of Saskatchewan
- Start
- Sep 2020
- Primary completion
- Sep 2026
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of IRDye800CW-nimotuzumab in non-small cell lung cancer (NSCLC), sponsored by University of Saskatchewan. Started Sep 2020; status: recruiting.
02
Drugs
IRDye800CW-nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04459065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459065.